Therefore, PPARβ/δ-specific agonists are attractive because PPARβ/δ activation can attenuate dyslipidemia, insulin resistance, hepatic steatosis, and inflammation [47,48,62,63,64]. Here, PPARD is linked to fatty liver disease.